Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
Status:
Terminated
Trial end date:
2014-05-15
Target enrollment:
Participant gender:
Summary
Allogeneic stem cell transplantation is a potentially curative treatment for patients with
many hematologic malignancies (e.g. leukemia, lymphoma, and myeloma with high risk of
relapse). This process requires a suitable donor. The best case scenario involves an Human
Leukocyte Antigen (HLA) matched sibling donor. However, this type of donor is not always
available. Donor registries can provide another source for matched unrelated donors, but this
may take valuable time delaying treatment for the transplant recipient. Donor availability
remains a significant barrier to the use of allogeneic (from a donor) stem cell transplant.
This issue disproportionately affects patients of minority backgrounds. Novel strategies to
improve outcomes using alternative donors are desperately needed.
Haploidentical transplants are an alternative which provides a readily available donor in the
form of a partially HLA matched family member. This provides for more potential donors and
the donors can be selected based on other factors that can play a role in transplant success
(e.g. age, gender, KIR alloreactivity). Recent advances in transplant techniques have greatly
improved success rates with haploidentical transplants although disease relapse has remained
as issue.
This trial aims to provide an alternative transplant option for patients with hematologic
malignancies who require bone marrow transplantation but lack an HLA identical donor. The
investigational component of this study is the combination of the Fludarabine/ Busulfan/
Total Body Irradiation conditioning regimen and the HLA Haploidentical Transplant with
post-transplant Cyclophosphamide.